MedPath

Experimental Exposure to Air Pollutants and Sympathetic Nerve Activity in Human Subjects

Not Applicable
Conditions
Cardiovascular Morbidity
Registration Number
NCT01914783
Lead Sponsor
Hannover Medical School
Brief Summary

The primary hypothesis of the study is that in healthy elderly subjects experimental exposure to air pollutants increases sympathetic nervous system activity compared with sham (clean air) exposure. The secondary hypothesis of the study is that combined experimental exposure to air pollutants (particles + ozone) increases sympathetic nervous system activity to a greater extent than does the exposure to particles alone.

Detailed Description

In a randomized, double-blind, and cross-over fashion, the participants will be exposed to clean air, ultrafine particles, or ultrafine particles and ozone in an exposure chamber. The investigators will determine blood pressure, heart rate, respiration as well as cardiac output and directly record sympathetic vasomotor tone using the microneurography technique. To elucidate the underlying mechanisms through which particles and ozone affect the autonomic nervous system, the investigators will assess the local and systemic inflammatory response as well as the changes in neurotrophic factors in sputum and blood. In addition, the activation of inflammatory cells in sputum and blood will be analyzed at different points in time after exposures. Changes in sympathetic activity will be correlated with the degree of airway inflammation and oxidative stress assessed in induced sputum and blood. This study will provide important insight in the mechanisms through which air pollution, particularly ultrafine particle exposure, increases cardiovascular risk in human subjects and generate a human model for mechanistic and therapeutic studies.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Elderly man or postmenopausal woman older than 50 years of age.
  • Signed written informed consent.
Exclusion Criteria
  • Smoker.
  • Cardiovascular and/or pulmonary disease.
  • Medication with relevant impact on autonomic system function, e. g. norepinephrine reuptake inhibitors. Stable medication with slight to moderate autonomic effects is tolerable.
  • Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
  • Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
  • Subject unlikely to comply with protocol, e. g. uncooperative attitude or unlikelihood of completing the study.
  • Known hypersensitivity to ozone.
  • History of drug or alcohol abuse. Particles Study - Protocol version: October 19, 2012 14
  • Blood donation of more than 500 mL during the previous 3 months.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Muscle sympathetic nerve activity (MSNA)2.5 hours after exposure to clean air, to ultrafine particles, or to a combination of ultrafine particles and ozone

Change of sympathetic vasoconstrictor nerve activity directed to skeletal muscle expressed as sympathetic bursts per minute. The primary hypothesis of the study is that in healthy elderly subjects experimental exposure to air pollutants increases sympathetic nervous system activity compared with sham (clean air) exposure.

Secondary Outcome Measures
NameTimeMethod
MSNA burst incidence2.5 hours after exposure to clean air, to ultrafine particles, or to a combination of ultrafine particles and ozone

Change of MSNA expressed as bursts/100 heart beats.

total MSNA2.5 hours after exposure to clean air, to ultrafine particles, or to a combination of ultrafine particles and ozone

Change of MSNA expressed as burst area/min.

Trial Locations

Locations (1)

Hannover Medical School

🇩🇪

Hannover, Germany

Hannover Medical School
🇩🇪Hannover, Germany
Marcus May, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.